Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities
- 1 August 2020
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 19 (8), 102586
- https://doi.org/10.1016/j.autrev.2020.102586
Abstract
No abstract availableFunding Information
- Array BioPharma
- Genentech
This publication has 21 references indexed in Scilit:
- Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort studyAnnals Of The Rheumatic Diseases, 2018
- Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysisEuropean Journal of Cancer, 2017
- Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragmAnnals of Oncology, 2016
- Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety StudyArthritis & Rheumatology, 2014
- Clinical cardiac involvement in idiopathic inflammatory myopathies: A systematic reviewInternational Journal of Cardiology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- The programmed death 1/programmed death ligand 1 inhibitory pathway is up‐regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritisArthritis & Rheumatism, 2010
- VigiBase, the WHO Global ICSR Database System: Basic FactsDrug Information Journal, 2008
- Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trialThe Lancet, 2008
- Association of the PD‐1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitopeArthritis & Rheumatism, 2004